Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
John Ryals
AddedMar 31, 2024
UpdatedMay 31, 2026
John Ryals

John Ryals

Board Member, Metabolon

CrunchbaseLinkedIn

John Ryals's Career

Metabolon
Metabolon

Durham, NC, US

Board Member· Board
EvoAktiv
EvoAktiv

Newton Grove, NC, US

Board Member· Board
AgBiome
AgBiome

Triangle (historical), NC, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

John Ryals's Career

Metabolon
Metabolon
Public$199.7M3022000Durham, NC, US
Board Member· Board

Leadership at Metabolon

Christopher KerseyChristopher KerseyBoard Member
John OxaalJohn OxaalBoard Member
Paul SchimmelPaul SchimmelCo-Founder
Tom CaskeyTom CaskeyBoard Member
Jeff ClarkJeff ClarkBoard Member
Jan LundbergJan LundbergBoard Member

Similar to Metabolon

Molecular BiometricsMolecular BiometricsNorwood, MA, USHealth Diagnosticsest. 2005Molecular BiometricsNorwood, MA, US · est. 2005

Molecular Biometrics develops non-invasive methods using metabolomic technologies for health evaluation.

Series B · $24.5M30
Panome BioPanome BioSt. Louis, MO, USBiomarker Discoveryest. 2022Panome BioSt. Louis, MO, US · est. 2022

Panome Bio: A next-gen biomarker discovery platform offering comprehensive metabolomics solutions, founded in 2022.

Series A · $6M13
Phenomix SciencesPhenomix SciencesRochester, MN, USBiotechest. 2017Phenomix SciencesRochester, MN, US · est. 2017

Phenomix Sciences: A biotech firm excelling in life science, metabolomics, and genomics.

Pre-Seed · $3.2M5
QuanterixQuanterixBillerica, MA, USBiomarker Analysisest. 2007QuanterixBillerica, MA, US · est. 2007

Quanterix: Advancing precision health science through digitized biomarker analysis in Lexington, US.

Public · $533.3M125
EvoAktiv
EvoAktiv
Series A$500k52014Newton Grove, NC, US
Board Member· Board

Leadership at EvoAktiv

Max SchaferMax SchaferCEO
Nadine SchaferNadine SchaferFounder

Similar to EvoAktiv

Evolved By NatureEvolved By NatureMedford, MA, USBiomaterials, Skincareest. 2013Evolved By NatureMedford, MA, US · est. 2013

Evolved By Nature: A biotech firm using Activated Silk™ tech for healthier, sustainable solutions.

Series C · $190M103
EvolugateEvolugateGainesville, FL, USResearch Developmentest. 2005EvolugateGainesville, FL, US · est. 2005

Evolugate LLC: A leading technology provider for micro-organisms research and development since 2005.

Seed · $240.2k30
TerMirTerMirRaleigh, NC, USAgricultural Productsest. 2016TerMirRaleigh, NC, US · est. 2016

TerMir: A biotech AgTech firm providing innovative solutions for agronomic and environmental challenges.

Angel · $544k6
Kiwa Bio-Tech Products GroupKiwa Bio-Tech Products GroupClaremont, CA, USAgricultural Productsest. 1999Kiwa Bio-Tech Products GroupClaremont, CA, US · est. 1999

Kiwa Bio-Tech innovatively develops and markets eco-friendly bio-tech products for agriculture and conservation.

Public16
AgBiome
AgBiome
Series D$252.5M1392012Triangle (historical), NC, US
Co-Founder

Leadership at AgBiome

Paul Schulze-LefertPaul Schulze-LefertCo-Founder
Kristina BurowKristina BurowBoard Member
Scott UknesScott UknesCo-Founder
Marijn DekkersMarijn DekkersBoard Member
Alison LawtonAlison LawtonBoard Member
Amir NashatAmir NashatBoard Member

Similar to AgBiome

Boost BiomesBoost BiomesSouth San Francisco, CA, USBiological Productsest. 2016Boost BiomesSouth San Francisco, CA, US · est. 2016

Boost Biomes, Inc.: Innovating unique biological products through proprietary microbiome technology in the US.

Series A · $4.2M
Ascribe BioscienceAscribe BioscienceIthaca, NY, USCrop Protectionest. 2017Ascribe BioscienceIthaca, NY, US · est. 2017

Ascribe Bioscience: Developing eco-friendly products to boost crop defenses against pathogens since 2017.

Seed · $7.2M8
AgrynexAgrynexIthaca, NY, USBiopesticides, Crop Protectionest. 2015AgrynexIthaca, NY, US · est. 2015

Agrynex: Providing biocidal enzymes for crop protection against soil-borne diseases.

Angel · $50k4
Pivot BioPivot BioBerkeley, CA, USAgricultural Productsest. 2010Pivot BioBerkeley, CA, US · est. 2010

Pivot Bio, Inc.: A US-based AgriTech firm innovating plant nutrition by harnessing atmospheric nitrogen.

Series D · $616.9M488

John Ryals's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to John Ryals

John CurtisJohn CurtisCEO · TherioBobby YazdaniBobby YazdaniFounder · Signatures CapitalAlon LevinAlon LevinCo-Founder · MamayaRonald GoldRonald GoldBoard Member · NJ BioJeremy AllaireJeremy AllaireBoard Member · Ping IdentityJuan EnriquezJuan EnriquezFounder & CEO · Biotechonomy